Evidence map›Paper›PMID 26385474›Full record

ArticleActa neuropathologica2015

PDCD10 (CCM3) regulates brain endothelial barrier integrity in cerebral cavernous malformation type 3: role of CCM3-ERK1/2-cortactin cross-talk.

Svetlana M Stamatovic, Nikola Sladojevic, Richard F Keep, Anuska V Andjelkovic

Abstract read
In one paragraph

Article in Acta neuropathologica, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 61 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. MAPK signaling and angiopoietin-2 contribute to endothelial permeability in capillary malformations.Proceedings of the National Academy of Sciences of the United States of America · 2025
    Article
  5. Article
  6. Profiling Tight Junction Protein Expression in Brain Vascular Malformations.International journal of molecular sciences · 2025
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Perfusion and permeability as diagnostic biomarkers of cavernous angioma with symptomatic hemorrhage.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2021
    Article
  18. Bringing CCM into a dish: cell culture models for cerebral cavernous malformations.Medizinische Genetik : Mitteilungsblatt des Berufsverbandes Medizinische Genetik e.V · 2021
    Article
  19. Toxins · 2021
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Svetlana M StamatovicDepartment of Pathology, University of Michigan, Medical School, 7520A MSRB I, 1150 W Medical Center Dr, Ann Arbor, MI, 48109-5602, USA.
Nikola SladojevicDepartment of Pathology, University of Michigan, Medical School, 7520A MSRB I, 1150 W Medical Center Dr, Ann Arbor, MI, 48109-5602, USA.
Richard F KeepDepartment of Neurosurgery, University of Michigan, Medical School, R5018 BSRB, 109 Zina Pitcher Place, Ann Arbor, MI, 48109-2200, USA.
Anuska V AndjelkovicDepartment of Pathology, University of Michigan, Medical School, 7520A MSRB I, 1150 W Medical Center Dr, Ann Arbor, MI, 48109-5602, USA. anuskaa@med.umich.edu.
University of Michigan–Ann Arbor · US

Funding

The mechanism of blood brain barrier impairment in cerebral cavernous malformatioR21NS075757 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDJELKOVIC-ZOCHOWSKA, ANUSKA V. · 2011 to 2012
$428k
NINDS NIH HHS NS075757NINDS NIH HHS R21 NS075757
6 · The paper itself

Abstract

Impairment of brain endothelial barrier integrity is critical for cerebral cavernous malformation (CCM) lesion development. The current study investigates changes in tight junction (TJ) complex organization when PDCD10 (CCM3) is mutated/depleted in human brain endothelial cells. Analysis of lesions with CCM3 mutation and brain endothelial cells transfected with CCM3 siRNA (CCM3-knockdown) showed little or no increase in TJ transmembrane and scaffolding proteins mRNA expression, but proteins levels were generally decreased. CCM3-knockdown cells had a redistribution of claudin-5 and occludin from the membrane to the cytosol with no alterations in protein turnover but with diminished protein-protein interactions with ZO-1 and ZO-1 interaction with the actin cytoskeleton. The most profound effect of CCM3 mutation/depletion was on an actin-binding protein, cortactin. CCM3 depletion caused cortactin Ser-phosphorylation, dissociation from ZO-1 and actin, redistribution to the cytosol and degradation. This affected cortical actin ring organization, TJ complex stability and consequently barrier integrity, with constant hyperpermeability to inulin. A potential link between CCM3 depletion and altered cortactin was tonic activation of MAP kinase ERK1/2. ERK1/2 inhibition increased cortactin expression and incorporation into the TJ complex and improved barrier integrity. This study highlights the potential role of CCM3 in regulating TJ complex organization and brain endothelial barrier permeability.

Indexed as

ActinsApoptosis Regulatory ProteinsBlood-Brain BarrierCapillary PermeabilityCells, CulturedCortactinCytosolEndothelial CellsHumansIntellectual DisabilityMAP Kinase Signaling SystemMembrane ProteinsMicrognathismProteasome Endopeptidase ComplexProto-Oncogene ProteinsRibsActinsApoptosis Regulatory ProteinsCortactinCTTN protein, humanMembrane ProteinsPDCD10 protein, humanProteasome Endopeptidase ComplexProto-Oncogene ProteinsRNA, MessengerTJP1 protein, humanZonula Occludens-1 ProteinBrain endothelial barrierCCM3CortactinPermeabilityTight junction

Identifiers

PMID26385474
PMCPMC4618087
OpenAlexW2176521677

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.